SCHEMBL6193992

SCHEMBL6193992

COC(=O)C(C)(C)Oc1cccc(-c2cccnc2)c1.COC(=O)C(C)(C)Oc1cccc(C2CCCNC2)c1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BCL9 O00512 8/20 0.43
CTNNB1 P35222 8/20 0.43
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
CHEK1 O14757 4/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
ABL1 P00519 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
CDK2AP1 O14519 1/20 0.38
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6193108 0.95 BCL9 (0.43) BCL9CTNNB1MKNK1MKNK2CHEK1
SCHEMBL6193112 0.95 BCL9 (0.43) BCL9CTNNB1MKNK1MKNK2CHEK1
SCHEMBL4028234 0.88 BCL9 (0.52) BCL9CTNNB1
SCHEMBL4027810 0.88 BCL9 (0.52) BCL9CTNNB1
SCHEMBL5362032 0.88 BCL9 (0.52) BCL9CTNNB1
SCHEMBL4028110 0.82 CYP11B2 (0.51) MKNK1MKNK2ABL1CYP19A1CYP11B1
Cadaverine Tartrate SCHEMBL4027502 0.81 BCL9 (0.49) BCL9CTNNB1
SCHEMBL5505486 0.77 BCL9 (0.54) BCL9CTNNB1
SCHEMBL5348343 0.77 PPARA (0.48) BCL9CTNNB1
SCHEMBL5361918 0.77 PPARA (0.48) BCL9CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567493-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS Pfizer Products Inc. (US) 2005-08-31 EP disclosed
WO-2004048334-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PRODUCTS INC. (US) 2004-06-10 WO disclosed